Patents by Inventor Christopher Sean Straub

Christopher Sean Straub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES
    Publication number: 20230321067
    Abstract: The present disclosure relates to dosing regimens comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions, pharmaceutical formulations, or combinations comprising the same; and methods of using such compounds, combinations, and compositions in the treatment or prevention IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, for example, the treatment of cancers.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 12, 2023
    Inventors: Eva Marie Genevieve D'HENNEZEL, Yi GU, Lisa Marie KATTENHORN, Fariba KHANSHAN, Eunice Lee KWAK, Joanne Choi RANDOLPH, Christopher Sean STRAUB
  • Dimeric IAP inhibitors
    Patent number: 8993523
    Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Christopher Sean Straub
  • Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof
    Patent number: 8906936
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: December 9, 2014
    Assignee: Novartis AG
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS
    Publication number: 20140004101
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicant: NOVARTIS AG
    Inventors: Zhuoliang Chen, Christine Hiu-Tung Chen, Mark G. Charest, Miao Dai, Feng He, Lei Huangshu, Ly Luu Pham, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming David Wang, Fan Yang, Leigh Zawel
  • DIMERIC IAP INHIBITORS
    Publication number: 20130309247
    Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.
    Type: Application
    Filed: December 13, 2011
    Publication date: November 21, 2013
    Applicant: NOVARTIS AG
    Inventors: Zhuoliang Chen, Christopher Sean Straub
  • DIMERIC IAP INHIBITORS
    Publication number: 20130266590
    Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I), (II), (III) or (IV) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.
    Type: Application
    Filed: December 13, 2011
    Publication date: October 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Christopher Sean Straub, Zhuoliang Chen
  • (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses
    Patent number: 8552003
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: October 8, 2013
    Assignee: Novartis AG
    Inventors: Mark G. Charest, Christine Hiu-Tung Chen, Zhuoliang Chen, Miao Dai, Feng He, Huangshu Lei, Ly Luu Pham, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming David Wang, Fan Yang, Leigh Zawel
  • SMAC peptidometics useful as IAP inhibitors
    Patent number: 8546336
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 1, 2013
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Mark G. Charest, Christine Hiu-Tung Chen, Miao Dai, Feng He, Huangshu Lei, Ly Luu Pham, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming David Wang, Fan Yang, Leigh Zawel
  • COMBINATION OF AN IAP INHIBITOR AND A TAXANE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE
    Publication number: 20130085153
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: July 12, 2012
    Publication date: April 4, 2013
    Inventors: Michael Rugaard Jensen, Christopher Sean Straub, Leigh Zawel, Mary Ann Tran, Youzhen Wang
  • SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS
    Publication number: 20130005663
    Abstract: The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Mark G. CHAREST, Christine Hiu-Tung CHEN, Zhuoliang CHEN, Miao DAI, Feng HE, Huangshu LEI, Ly Luu PHAM, Sushil Kumar SHARMA, Christopher Sean STRAUB, Run-Ming David WANG, Fan YANG, Leigh ZAWEL
  • Inhibitors of IAP
    Patent number: 8338440
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: December 25, 2012
    Inventors: Mark G. Palermo, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming Wang, Leigh Zawel, Yanlin Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark G. Charest, Feng He
  • Inhibitors of IAP
    Patent number: 8207183
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 26, 2012
    Assignee: Novartis AG
    Inventors: Mark G. Palermo, Sushil Kumar Sharma, Christopher Sean Straub, Run-Ming Wang, Leigh Zawel, Yanling Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark G. Charest, Feng He
  • Organic Compounds
    Publication number: 20110319614
    Abstract: The present invention relates to novel IAP inhibitor compounds of formula I:
    Type: Application
    Filed: September 8, 2011
    Publication date: December 29, 2011
    Applicant: NOVARTIS AG
    Inventors: Zhuoliang CHEN, Run-Ming David WANG, Ming CHEN, Christopher Sean STRAUB, Leigh ZAWEL
  • Organic compounds
    Patent number: 8058272
    Abstract: The present disclosure relates to XIAP inhibitor compound of the formula I:
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: November 15, 2011
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Run-Ming David Wang, Ming Chen, Christopher Sean Straub, Leigh Zawel
  • Substituted pyrazine-3-one-derivatives as IAP inhibitors
    Patent number: 8048886
    Abstract: The present invention relates to novel IAP inhibitor compounds of formula I:
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: November 1, 2011
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Run-Ming David Wang, Ming Chen, Christopher Sean Straub, Leigh Zawel
  • Pyrrolydine derivatives as IAP inhibitors
    Patent number: 8044209
    Abstract: The present invention relates to novel IAP inhibitor compounds of: Formula (I).
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: October 25, 2011
    Assignee: Novartis AG
    Inventors: Mark G. Charest, Christine Hiu-Tung Chen, Ming Chen, Zhuoliang Chen, Miao Dai, Feng He, Huangshu Lei, Christopher Sean Straub, Run-Ming David Wang, Leigh Zawel
  • DIMERIC IAP INHIBITORS
    Publication number: 20110206690
    Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 25, 2011
    Applicant: NOVARTIS AG
    Inventors: Christopher Sean STRAUB, Zhuoliang CHEN, Mark G. PALERMO
  • Combinations of Organic Compounds
    Publication number: 20100324083
    Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: August 25, 2010
    Publication date: December 23, 2010
    Inventors: Michael Rugaard JENSEN, Christopher Sean STRAUB, Leigh ZAWEL, Mary Ann TRAN, Youzhen WANG
  • Organic Compounds
    Publication number: 20100316573
    Abstract: A method to predict which patients will respond to a IAP inhibiting compound comprising: a) administering an IAP inhibitor compound to a patient, and b) measuring TNF-? or IL-? levels.
    Type: Application
    Filed: October 17, 2007
    Publication date: December 16, 2010
    Inventors: Larry Alexander Gaither, Vadim Iourgenko, Mark Aron Labow, Dale Alan Porter, Christopher Sean Straub, Yao Yao, Leigh Zawel
  • Organic Compounds
    Publication number: 20100249405
    Abstract: The present invention relates to novel IAP inhibitor compounds of formula I:
    Type: Application
    Filed: December 7, 2007
    Publication date: September 30, 2010
    Inventors: Zhuoliang Chen, Run-Ming David Wang, Ming Chen, Christopher Sean Straub, Leigh Zawel